first crypto currency Top Knowledge

Nigeria: About 130,000 members of Boko Haram have surrendered in the past five months. Christopher Moussa, chief of staff of Nigeria's defense, said on the 12th that nearly 130,000 members of the extremist organization Boko Haram have surrendered in the past five months. Moussa, attending the African Security Watch Conference in Doha, Qatar, said that from July 10th to December 9th, a total of 30,426 Boko Haram militants, 36,774 women and 62,265 children members of the organization surrendered. (Xinhua News Agency)Barclays: The Central Economic Work Conference released more signals of policy support, which was held in Beijing from December 11th to 12th. The Barclays research team said that the Central Economic Work Conference provided more forward-looking guidance and released more policy support signals. Barclays said that on the whole, the meeting made it clear that "stable economic growth should be maintained next year" and emphasized "implementing more active macro policies" and "vigorously boosting consumption". The agency believes that regulators are more likely to introduce policies in a gradual manner. At the same time, when measuring the rhythm, scale and composition of the next round of measures, we should focus on the development and changes of real estate and stock market. Barclays expects that a more specific financial plan will be announced in March next year. In terms of monetary policy, the meeting proposed to implement a "moderately loose monetary policy". Barclays believes that this change in wording and position has released a positive signal, especially considering the current environment, it is expected that the central bank may cut interest rates significantly in the future. (SSE)Zhengzhou Investment Holding Company increased its capital to 7.78 billion yuan, with an increase of about 121%. Tianyancha App shows that Zhengzhou Investment Holding Co., Ltd. has undergone industrial and commercial changes recently, adding Zhengzhou Development Investment Group Co., Ltd. as a shareholder, and its registered capital has increased from about 3.53 billion yuan to about 7.78 billion yuan, with an increase of about 121%. At the same time, many senior executives have changed. Zhengzhou Investment Holding Co., Ltd. was established in October 2005, and its legal representative is Yu Jianwei. Its business scope covers state-owned assets investment and management, real estate development and sales, and house leasing. Now Zhengzhou Zhongrongchuang Industrial Investment Co., Ltd. and the above-mentioned newly-added shareholders jointly hold shares.

Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Hailide: PPS filament products have not yet been involved in the field of humanoid robots. Hailide said on the interactive platform on December 13th that the company has been deeply involved in the field of materials for many years, and with the continuous investment in research and development, the commercialization of PPS filament has been realized. At present, the product has not yet been involved in the field of humanoid robots. In the future, the company will strive to gradually realize mass production applications in related emerging fields, and is full of confidence in this.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.

Dutch International: Britain's economic growth momentum has further slowed down, but the budget boost is coming. Dutch International Bank said that Britain's GDP fell again in October, although this may exaggerate the degree of recent economic slowdown. According to the bank's forecast of Britain's annual GDP in 2025, the British economy will surpass most western European countries next year. This may tell more about the economic health of other parts of continental Europe, but it also reflects the impact of the recent fiscal stimulus measures in Britain to a great extent. Compared with the budget of the last Conservative government, public expenditure has increased by about 60 billion pounds, accounting for more than 2% of GDP. Most of the increased expenditure will flow to government departments in the form of daily funds, and most of it will eventually appear in the form of wages. Therefore, the transmission of finance to broader economic growth may be quite high.Shenzhen Stock Exchange: The Shenzhen Stock Exchange, together with the Financial Office of Henan Provincial Party Committee, Henan Securities Regulatory Bureau and Zhengzhou Municipal Party Committee and Municipal Government, jointly held an industrial exchange meeting on "Shenzhen M&A Revitalizing Quality". This activity focused on the advantageous industries of high-end equipment manufacturing in Henan Province, discussed in depth the development characteristics of the industry and the main points of M&A investment, built an exchange platform, conveyed the concept of supervision, supported the integration of upstream and downstream of the industrial chain, strictly prevented insider trading in M&A and reorganization, and helped Henan develop new quality productivity according to local conditions. Next, Shenzhen Stock Exchange will continue to implement the requirements of "Six Articles on M&A" in accordance with the unified deployment of China Securities Regulatory Commission, adhere to the direction of marketization, adhere to the major strategy of serving the country, give full play to the role of the capital market as the main channel in enterprise M&A and reorganization, take various measures to support listed companies to standardize M&A and reorganization, promote the landing of high-quality cases, strengthen exchanges with market players, and strive to create a healthy and orderly market ecology.To ensure that patients across the country will use the drugs selected in April next year, the tenth batch of drugs organized by the state will be opened for centralized procurement, and the tenth batch of drugs organized by the state will be selected in Shanghai yesterday, and 62 drugs will be purchased successfully. Covering hypertension, diabetes, tumors, cardiovascular and cerebrovascular diseases, infections, mental diseases and other fields. In the next step, the National Medical Insurance Bureau will guide local and selected enterprises to do a good job in the implementation of the selected results to ensure that patients across the country can use the selected products in this centralized collection in April 2025. (CCTV News)